Assenagon Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Assenagon Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,872	Closed	-$40K	–	1101
2025 Q4	$40K	Sell	24,872 -401,894	-94%	-$841K	﹤0.01%	1142
2025 Q3	$1.17M	Buy	+426,766	New	+$1.42M	﹤0.01%	904
2024 Q3	–	Sell	-211,647	Closed	-$216K	–	1360
2024 Q2	$216K	Sell	211,647 -578,836	-73%	-$715K	﹤0.01%	1360
2024 Q1	$1.45M	Buy	+790,483	New	+$1.26M	﹤0.01%	971
2023 Q2	–	Sell	-12,450	Closed	-$6.98K	–	1321
2023 Q1	$6.98K	Buy	+12,450	New	+$9.51K	﹤0.01%	1398
2022 Q2	–	Sell	-104,092	Closed	-$75K	–	1445
2022 Q1	$75K	Buy	+104,092	New	+$223K	﹤0.01%	1385
2020 Q1	–	Sell	-12,146	Closed	-$77K	–	770
2019 Q4	$77K	Buy	+12,146	New	+$57.7K	﹤0.01%	740

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Assenagon Asset Management's AKBA Position: Q1 2026 in Review

Assenagon Asset Management sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 24,872 shares — an estimated $40K sold.

Assenagon Asset Management first reported a position in AKBA in Q4 2019 and held it in 7 quarters. The position peaked at $1.45M in Q1 2024. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Assenagon Asset Management reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
Assenagon Asset Management sold 24,872 Akebia Therapeutics shares in Q1 2026, an estimated $40K.
Assenagon Asset Management first reported a position in Akebia Therapeutics in Q4 2019 and held it in 7 quarters.
Assenagon Asset Management's Akebia Therapeutics position peaked at $1.45M in Q1 2024.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Assenagon Asset Management's 13F filing for Q1 2026, filed 20 Apr 2026.